Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-78.4%

“The 2025 effective tax rate was driven higher by a non-deductible goodwill impairment and an investment basis difference on the sale of the Jada System, offset by the favorable impact of a tax amortization benefit.”

Read it in the 10-K

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

58.0% to 53.3% (-4.7 pts)

“Gross profit decreased 11% for the year ended December 31, 2025, compared to 2024, due to increased costs to optimize our manufacturing and supply network, the impact of unfavorable pricing, volume and product mix, partially offset by foreign exchange.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-25.5%

“Net cash provided by operating activities was $700 million for the year ended December 31, 2025, compared to $939 million for the same period in the prior year due to lower operating income, partially offset by our active cash cycle management.”

Read it in the 10-K

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

-2.9%

“This decrease in the above sales was offset by sales increases for the year ended December 31, 2025 in:”

Read it in the 10-K

“Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, declined 4% for the year ended December 31, 2025, compared to 2024, primarily due to decreased demand related to policy related access restrictions and lower physician demand, coupled with increased discount rates in the United States, partially offset by increased demand in Brazil and our institutional business.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 -2.9%

    “This decrease in the above sales was offset by sales increases for the year ended December 31, 2025 in:”

    Read it in the FY 2025 10-K

    “Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, declined 4% for the year ended December 31, 2025, compared to 2024, primarily due to decreased demand related to policy related access restrictions and lower physician demand, coupled with increased discount rates in the United States, partially offset by increased demand in Brazil and our institutional business.”

    Read it in the FY 2025 10-K
  • FY 2024 +2.2%

    “Excluding foreign exchange, sales increases for the year ended December 31, 2024, primarily reflect the performance of:”

    Read it in the FY 2024 10-K

    “LOE negatively impacted sales of certain of our products by approximately $57 million during the year ended December 31, 2024, based on the decrease in volume period over period, which was primarily driven by the LOE of Atozet in France, Spain, and Japan.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 -4.7 pts

    “Gross profit decreased 11% for the year ended December 31, 2025, compared to 2024, due to increased costs to optimize our manufacturing and supply network, the impact of unfavorable pricing, volume and product mix, partially offset by foreign exchange.”

    Read it in the FY 2025 10-K
  • FY 2024 -1.8 pts

    “Cost of sales increased 7% for the year ended December 31, 2024, compared to 2023, primarily due to higher sales volume, higher inflation impacts to material and distribution costs and amortization of $7 million associated with the inventory fair value adjustment related to the Dermavant acquisition purchase accounting, partially offset by foreign exchange translation.”

    Read it in the FY 2024 10-K

    “Gross profit decreased 1% for the year ended December 31, 2024, compared to 2023, due to the impact of unfavorable price, foreign exchange translation and higher inflation impacts to material and distribution costs partially offset by increased sales due to volume.”

    Read it in the FY 2024 10-K

Net income

1 of 2 years explained
  • FY 2025 -78.4%

    “The 2025 effective tax rate was driven higher by a non-deductible goodwill impairment and an investment basis difference on the sale of the Jada System, offset by the favorable impact of a tax amortization benefit.”

    Read it in the FY 2025 10-K
  • FY 2024 -15.5%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

2 of 2 years explained
  • FY 2025 -25.5%

    “Net cash provided by operating activities was $700 million for the year ended December 31, 2025, compared to $939 million for the same period in the prior year due to lower operating income, partially offset by our active cash cycle management.”

    Read it in the FY 2025 10-K
  • FY 2024 +17.5%

    “The increase in cash provided by operating activities was primarily attributable to our favorable operating performance and cash cycle working capital, partially offset by higher cash taxes paid and higher severance-related payments.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.